Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
Clinical trial NCT04646005 · COMPLETED
Trial details
- NCT number
- NCT04646005
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-28
- Primary completion
- 2023-05-22
- Enrollment
- 113
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.